OBJECTIVE: We examined the relationship of adiposity to pituitary ± adrenal responses to corticotrophin-releasing hormone (CRH) in men and postmenopausal women, controlling for the in¯uence of depression. DESIGN: Studies of CRH responses, cortisol metabolite levels and depression scores in relation to adiposity in men and postmenopausal women. SUBJECTS: Thirteen men: age (median, interquartile range) 62 y (52 ± 63), body mass index (BMI) 29.0 kgam 2 (26.3 ± 33.1), waist circumference (waist) 105 cm (97 ± 111), waist : hip ratio (WHR) 1.03 (0.98 ± 1.07), subscapular to triceps skinfold thickness ratio (STR) 2.0 (1.2 ± 2.4), total body fat (TBF) 25.4 kg (19.8 ± 28.8); and eight women: age 54 y (53 ± 62), BMI 30 kgam 2 (23 ± 41), waist 86 cm (79 ± 117), WHR 0.94 (0.87 ± 1.10), STR 1.0 (0.85 ± 1.07), TBF 35.0 kg (18.7 ± 48.8). MEASUREMENTS: A standard CRH test was conducted with additional basal samples taken for leptin and interleukin 6 (IL-6). Total urine cortisol metabolites (TCM) and the ratio of urinary cortisol : cortisone (FmaEm) metabolites were measured. Depression scores were measured by the General Health Questionnaire (GHQ-30) and Hospital Anxiety and Depression Scale (HAD) questionnaire. All subjects completed an overnight dexamethasone suppression test. RESULTS: The basal to peak percentage increments (%inc.) in adrenocorticotrophic hormone (ACTH) and cortisol in men correlated directly with STR (ACTH %inc. r 0.70, P`0.01; cortisol %inc. r 0.55, P 0.05); this relationship was independent of depression scores. In women, the ACTH area under incremental curve (AUIC) correlated negatively with STR (r À0.81, P`0.05). In men, but not in women, there was a signi®cant correlation between GHQ-30 score and ACTH AUIC (r 0.62, P`0.05) and cortisol AUIC (r 0.72, P`0.01). Depression scores were consistently and directly related to indices of obesity and central obesity. There were no signi®cant relationships in either sex between urinary TCM or FmaEm ratio and BMI, waist, WHR, TBF, STR or CRH responses. The urinary FmaEm ratio was higher in men than in women (median 0.74 vs 0.66, P`0.05). In men, but not in women, GHQ-30 scores correlated positively with urinary TCM (r 0.57, P 0.05) and HAD-depression scores were inversely related to the urine FmaEm ratio (r À0.65, P`0.05). All subjects suppressed normally with dexamethasone. CONCLUSIONS: Cortisol metabolite levels were increased in depression in men, but were not related to adiposity in either sex. We demonstrate that central obesity in men, but not postmenopausal women, is associated with an enhanced pituitary ± adrenal response to CRH and that this relationship is independent of depression score.
Introduction
The pituitary and adrenal response to provocation tests in obese premenopausal women has been extensively studied, 1 ± 5 but there is a lack of data on men and post-menopausal women. Centrally obese premenopausal women have been shown to have an enhanced ACTH and cortisol response to CRH 2 and some authors have extrapolated from these data to assert that a hyperactive hypothalamo ± pituitary ± adrenal (HPA) axis results in increased cortisol production rates, central obesity and insulin resistance. 6 We have set out to clarify whether adiposity or depression in¯uence CRH responses and cortisol metabolite levels in men and postmenopausal women. There is a growing body of in-vitro evidence to suggest that both leptin 7 ± 9 and IL-6 10 ± 12 have a regulatory role in HPA axis activity. We examine the relationship of pituitary and adrenal CRH responses to basal leptin and IL-6 levels.
Methods
Thirteen men and eight postmenopausal women were recruited from a primary health care practice and an obesity clinic. Their characteristics are outlined in Table 1 . No subjects were being treated with topical, inhaled or oral corticosteroid preparations or had received such treatment in the year prior to the study. Four of the women were taking hormone replacement therapy. The local ethical committee approved the study and informed consent was obtained from all volunteers.
At the initial visit a full medical history was taken. Five different indices of adiposity were measured: body mass index (BMI), waist circumference (waist), waist : hip ratio (WHR), total body fat (TBF) and subscapular : triceps skinfold thickness ratio (STR). Weight was measured using a digital weighing machine (Seca, Marsden, UK) to the nearest 0.1 kg. Height was measured using a Harpenden stadiometer (Holtain Ltd., Crymych, UK). TBF was measured by bioimpedance with the subjects recumbent and electrodes (Bodystat 1500, Bodystat Ltd, Douglas, UK) attached to the dominant side. Skinfold thickness was measured with a pair of calipers (Holtain Ltd., Crymych, UK). Subscapular skinfold thickness was measured immediately below the tip of the scapula with the skinfold at an angle of 45 to the vertical. The triceps skinfold was measured in a vertical plane at the mid-point between the acromion process of the scapula and the tip of the olecranon process. Waist and hip circumference were both measured in a transverse plane, at the level of the umbilicus and greater trochanters respectively.
All subjects completed a 24-h urine collection for urine cortisol metabolites immediately prior to the corticotrophin-releasing hormone (CRH) test. Subjects fasted overnight and a cannula was inserted in the antecubital fossa at 8 am. They rested supine for at least 30 minutes before the ®rst blood sample was taken. They remained supine for the duration of the test. At 9 am CRH (100 mg human CRH, Ferring Pharmaceuticals Ltd.) was injected intravenously. Serum and ethylenediaminetetra-acetic acid (EDTA) samples were collected at À15, 0, 15, 30, 45, 60, 90 and 120 minutes after CRH administration. EDTA samples for ACTH, leptin and IL-6 analysis were stored on ice, centrifuged (4 C) and frozen (À20 C) within an hour. Serum samples were centrifuged at room temperature and stored (À20 C).
Overnight dexamethasone suppression tests
At least two weeks after the CRH test, all subjects took 2 mg of dexamethasone at 11 pm. The following morning at 8 am, a serum sample was taken from each subject for cortisol assay.
Depression scores
After completing the CRH test all subjects completed two questionnaires to assess depression scores. The GHQ-30 and HAD questionnaires are validated methods of rating depression scores. 13 The range of possible scores in the GHQ is from 0 ± 30, scores b 5 representing signi®cant depression. The HAD questionnaire measures depression (possible range 0 ± 21), scores of greater than 9a21 representing signi®cant depression.
Assays
Serum cortisol was measured with the Bayer Immuno-1 automated analyser; inter-assay imprecision for cortisol at 140, 417 and 948 nmolal was 5.5, 3.6 and 3.5% respectively. Plasma ACTH was measured using the Nicholls immunoradiometric kit; inter-assay imprecision for ACTH at 50 and 400 ngal was 8.8% and 7.3% respectively. Plasma leptin was measured with an in-house radioimmunoassay (utilising a polyclonal antibody raised in a rabbit host) with an interassay imprecision of 5.0%. Plasma IL-6 was measured using an ELISA kit (R&D Systems, Oxon, UK) with an inter-assay imprecision of 6.7%.
Urine cortisol metabolites
In all subjects total urine cortisol metabolites and creatinine were measured in an aliquot of their 24-h collection. Urine steroid pro®les were analysed by high resolution gas chromatography. 14 Urinary total cortisol metabolites (TCM) are de®ned as the sum of urinary cortisol (11-hydroxy) metabolites (Fm) and urinary cortisone (11-oxo) metabolites (Em). All urine cortisol metabolite levels are expressed as mgammol creatinine to correct for the in¯uence of lean body mass.
Statistical analysis
ACTH and cortisol responses to CRH were assessed by two methods: the percentage increment (%inc.) from basal to peak value; and by the area under the incremental curve (AUIC). The relationships between 
a By GHQ-30 criteria (score ! 5) three men and one woman were depressed. b By HAD criteria (score ! 9) one man and two women were depressed. c Mann ± Whitney: signi®cantly higher in men (P`0.05).
adiposity, depression scores, urine cortisol metabolites and cortisolaACTH response to CRH were assessed by Spearman's rank correlation coef®cients. After log transformation of signi®cantly skewed variables, linear regression was used to account for confounding variables. The Mann ± Whitney test was applied to assess gender differences in adiposity, depression, urine cortisol metabolites and CRH response.
Results

Adiposity and CRH responses
The basal serum cortisol concentration was 347 (277 ± 496) nmolal and did not vary according to gender, BMI or body composition. The ACTH and cortisol %inc. and AUIC results for men and women are summarised in Table 2 . In men, there were strong positive correlations between STR and ACTHacortisol responses to CRH (Table 3 ). In postmenopausal women, there was an inverse correlation between STR and ACTH AUIC (r À0X81, P`0.05). There were non-signi®cant inverse correlations between other indices of adiposity and CRH responses in women. The women on HRT (n 4) closely matched those not on HRT (n 4) with regard to age, BMI and WHR. We found no signi®cant difference in CRH response between women on HRT and those not on HRT.
Depression scores in relation to CRH responses and adiposity
The depression scores in men and women are summarised in Table 1 . The correlations of depression scores with CRH responses in men are shown in Table  3 . In men, the GHQ-30 score was positively associated with all cortisol and ACTH responses to CRH. Multiple regression analysis con®rmed that STR and depression scores were related to CRH responses independently of one another. In women, there was no association between depression scores and ACTHacortisol responses to CRH. The relationship of adiposity to depression scores in men is summarised in Table 4 . Both GHQ-30 and HAD-depression scores correlated positively with BMI, waist and WHR. In women, HAD-depression scores correlated with WHR (r 0.70, P`0.05), but this was the only signi®cant relationship between depression scores and adiposity.
Urine cortisol metabolites vs obesity and depression
Urine cortisol metabolite results, depression scores and anthropometric data are summarised in Table 1 . Although there was no sex difference in TCM, the FmaEm ratio was signi®cantly higher in men than in women. There was no relationship between urinary TCM and ACTHacortisol responses to CRH in either sex. Depression scores in men, but not in women, correlated positively with urinary TCM and were inversely related to the urinary FmaEm ratio (see Table 4 ). Both TCM and the FmaEm ratio were unrelated to adiposity, as measured by BMI, WHR, TBF and STR in both sexes. This lack of a relationship persisted even when depressed patients (by either HAD or GHQ-30 criteria) were excluded from the analysis.
Dexamethasone suppression tests
In all subjects, plasma cortisol was suppressed tò 50 nmolal at 8 am, the morning after a 2 mg dose of dexamethasone had been administered.
Leptin
In men, basal leptin 8.5 (4.6 ± 10.4) ngaml correlated with ACTH AUIC (r 0.69, P`0.05) and BMI (r 0.73, P`0.01). However, multivariate analysis HPA activity in men and postmenopausal women JR Katz et al showed no effect of leptin independent of STR. There was a trend towards a correlation between leptin and cortisol incremental measures, but this failed to reach signi®cance. In women, basal leptin 16.1 (5.9 ± 31.0) ngaml correlated with BMI (r 0.79, P`0.05) but not with ACTH and cortisol responses to CRH.
Interleukin-6
In men, basal IL-6 concentrations of 3. 2 and an enhanced cortisol response to CRH, synthetic corticotropin and psychological stress. 15 Skinfold thickness re¯ects subcutaneous rather than visceral fat depots, but can be measured in subjects with a wide range of body habitus and this represents an advantage over other methodologies. Dual energy X-ray absorptiometry (DEXA) scanning of regional fat depots was not undertaken in this study as DEXA is less accurate in the very obese and morbidly obese subjects do not ®t on the table. There are similar methodological problems with computed tomographs (CT) and magnetic resonance imaging (MRI) (except where large diameter machines are available).
In men, there were consistent positive associations between pituitaryaadrenal responses to CRH and depression scores on the GHQ-30 questionnaire, independent of STR. This con¯icts with previous data, which has shown a blunted ACTH response and a normal cortisol response in depression. 16, 17 There were no signi®cant associations between depression and CRH responses in the female group. Depression has been shown to be associated with obesity and particularly central obesity 18 and this is con®rmed by our ®nding of positive correlations between depression scores and BMI, waist and WHR in men. We hypothesise that depression accounts for some of the inconsistencies in the literature regarding CRH responses in obesity. We have found a direct association between central obesity and CRH responses in men, independent of depression scores.
There are limited published data on CRH responses in centrally obese men, but our data are supported by preliminary data from another group. 19 Our data, in the context of previous studies 2 on premenopausal women, are consistent with its suggestion that the menopause may result in a diminished response to CRH. However, the lack of a relationship of central obesity to CRH responses in women may re¯ect the narrow range of STR in the female group, as compared to the male group in our study. There is no data as yet comparing CRH responses in large matched groups of menopausal women on and off hormone replacement therapy (HRT), but our preliminary data show no signi®cant difference between these groups.
Obesity per se, in contrast to body fat distribution, was unrelated to CRH responses in either sex. Although only 2a13 men and 4a8 women had a BMI`25 kgam À2 , both sexes had a wide range of BMI and this should be suf®cient to establish a correlation. Expanded normal weight control groups would have strengthened the analysis. However, our study is in agreement with most of the previous research in this area, which has shown normal ACTH 1, 3 and cortisol 3, 5 responses to CRH in obesity per se. Only one study has suggested a blunted cortisol 1 response to CRH in obese subjects compared to normal weight controls. Another group reported an increased ACTH, but normal cortisol response to CRH in obesity, 5 but higher doses of CRH were given to the most obese patients, which may explain this ®nding.
Total urine cortisol metabolite levels (TCM) can be utilised to re¯ect (or indicate) cortisol production rates. Correction for creatinine controls for the in¯u-ence of lean body mass. 20 There is some evidence to suggest that centrally obese subjects, when compared to subjects with generalised obesity, demonstrate an exaggerated increase in cortisol secretion in response to transient psychological stress. 15, 21 Furthermore, it has been suggested that a hyperactive HPA axis in central obesity leads to increased cortisol production rates. 6 However, we found no relationship of CRH responses or indices of adiposity with TCM and, in as far as urine cortisol metabolite levels re¯ect cortisol production rates, we were unable to con®rm this hypothesis in our study. We did not, however, formally assess cortisol production rates.
Although increased TCM have been reported in obesity, 22 we concur with two recent studies 23, 24 which demonstrated no signi®cant relationship between BMI and TCM in men and women. Increased urinary free cortisol (UFC) excretion has been demonstrated in centrally obese premenopausal women. 2, 15 However, UFC accounts for less than 1% of TCM and does not accurately re¯ect cortisol production rates. 23 We analysed and rejected the hypothesis that depression obscured a relationship between adiposity and urine cortisol metabolite pro®les. Whilst we found HPA activity in men and postmenopausal women JR Katz et al depression was associated directly with TCM in men only, previous studies have found a similar relationship in both men and women. 14, 25 Our ®nding of an inverse relationship between depression and urine FmaEm in men is at variance with one previous case-controlled study, which demonstrated no in¯u-ence of depression on the FmaEm ratio in men and an increased FmaEm ratio in depression in women. 14, 25 Direct comparisons between our study and Raven's study 14, 25 are dif®cult. The Raven study was casecontrolled, but there was no correction for lean body mass and they used a different depression scale.
The urine FmaEm ratio was higher in men than women in keeping with two previous studies. 14, 26 In our study, FmaEm did not relate to CRH responses or adiposity in either sex. There has been debate in the literature as to the direction of the cortisol ± cortisone shuttle in central obesity. Whilst Andrew et al 23 found a positive correlation of the FmaEm ratio with both hip circumference and waist circumference in men, they do not present their data on waist-hip ratio and have no other index of central obesity. Meanwhile, Stewart found that the FmaEm ratio is inversely related to android (central) fat distribution, 24 which is contrary to his group's in-vitro data on visceral adipose tissue. 27 Finally, Weaver et al 26 found the FmaEm ratio to be inversely related to body weight, android fat and gynoid fat, but stepwise regression con®rmed gynoid fat was the most important factor determining the FmaEm ratio. 26 Our data, in conjunction with these con¯icting papers, 23, 24, 26 suggests that the relationship of body fat distribution to the urine FmaEm ratio is, as yet, unclear.
Regarding the role of leptin and IL-6 in regulating the HPA axis, multivariate analysis demonstrated that the positive association between leptin and ACTH AUIC was not independent of STR. This is contrary to a regulatory role for leptin at hypothalamic or adrenal levels suggested by laboratory and animal studies.
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We did not ®nd a simple relationship between basal IL-6 levels and CRH responses. Previous work has suggested a close relationship between IL-6 and ACTH circadian rhythm 28 and IL-6 administration has been shown to activate the HPA axis both in animals 11, 12 and in humans. 10 Excessive alcohol consumption has been shown to blunt the ACTH and cortisol responses to CRH 29 and impair dexamethasone suppression of plasma cortisol. 30 We assessed alcohol intake in all subjects as part of the medical history. There were two men who drank in excess of 20 units per week, but they did not demonstrate blunted responses to CRH and suppressed normally with dexamethasone. Excluding them from the analysis did not alter the strength of the positive relationships. We do not believe alcohol intake was a confounding factor in our study.
We have considered whether HRT use acts as a confounding variable in the assessment of CRH responses in postmenopausal women. There is invitro evidence 31, 32 that oestrogen increases expression of the CRH gene. However, a previous clinical study 33 found no difference in the pituitary and adrenal responses to CRH between women on HRT and those not on HRT. Our study supports the view that HRT does not in¯uence the ACTH and cortisol responses to CRH, although the numbers of women taking HRT (four in our study and four in the previous study cited) were small. The role of oestrogen in modulating the CRH response in postmenopausal women needs to be addressed by further research.
Conclusions
Previous studies have shown an increased pituitary ± adrenal response to CRH in centrally obese premenopausal women. We have demonstrated that this effect extends to centrally obese men, but not to postmenopausal women, and is independent of depression score, basal leptin and IL-6 levels.
